22157.jpg
World Immune-checkpoint Drugs in Oncology Analytical Handbook 2022
08 juin 2022 03h18 HE | Research and Markets
Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Immune-checkpoint Drugs in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. Immune-checkpoint Drugs in Oncology:...
logo.jpg
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
08 avr. 2022 13h00 HE | ImCheck Therapeutics SAS
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Datafrom the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022         Continued positive safety data across a range of ICT01 doses...
Picture1.jpg
Oncotelic Presenting at BiotechGate Digital Partnering
19 janv. 2022 09h05 HE | Oncotelic Therapeutics, Inc.
OT-101 is Oncotelic’s RNA Therapeutic Against TGF-βOT-101 has completed over six clinical trials against solid tumors with good efficacyOT-101 is currently undergoing a phase 1b trial in combination...
Picture1.jpg
Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma
05 janv. 2022 08h01 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...
22157.jpg
Global Head & Neck Cancer Drugs Market Research Report (2021 to 2026) - by Drug Class, Product, End-user and Region
05 janv. 2022 06h33 HE | Research and Markets
Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Head & Neck Cancer Drugs Market Research Report by Drug Class, Product, End-user, and Region - Global Forecast to 2026 - Cumulative Impact of...
22157.jpg
Global Checkpoint Inhibitors Market (2021 to 2030) - Featuring AstraZeneca, Roche Holding and Pfizer Among Others
07 déc. 2021 06h58 HE | Research and Markets
Dublin, Dec. 07, 2021 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. This...
logo.jpg
ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021
01 oct. 2021 08h00 HE | ImCheck Therapeutics SAS
ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021 Marseille, France, October 1, 2021 – ImCheck Therapeutics today...
Aprea logo 445pt.png
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
20 sept. 2021 16h15 HE | Aprea Therapeutics
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
logo.jpg
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
17 sept. 2021 08h00 HE | ImCheck Therapeutics SAS
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021         First EVICTION data from checkpoint inhibitor-refractory solid tumor...
22157.jpg
China Pembrolizumab Market Report 2021: Market Size will Expand in the Future Due to the Increased Numbers of Approved Indications
19 avr. 2021 08h18 HE | Research and Markets
Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on the Chinese Pembrolizumab Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering. After Pembrolizumab...